Relia Biological secures pre-IPO equity financing, raises hundreds of millions of yuan

POCT equipment and reagent company Relia Biological announced that it has secured hundreds of millions of yuan in Pre-IPO equity financing in April 2020. This round of investment was led by the Health Industry Fund of CQ Pharmaceutical Holding, Feike Investment, Efung Capital, and other industry and financial investment institutions.

POCT equipment and reagent company Relia Biological announced that it has secured hundreds of millions of yuan in Pre-IPO equity financing in April 2020. This round of investment was led by the Health Industry Fund of CQ Pharmaceutical Holding, Feike Investment, Efung Capital, and other industry and financial investment institutions.

The company has hired a number of top-tier intermediaries including securities firms, law firms, etc., and will start the listing process on the STAR Market within the year.

Relia Biological has two series of POCT systems: multi-functional immunodetection system and immunofluorescence rapid detection system, including rapid detection series of cardiovascular diseases, acute kidney injury detection series and inflammation, infectious disease rapid detection series, etc. The company holds more than 20 domestic and foreign patents and more than 50 product certificates.

Relia Biological was established in 2001. The R&D center is located in Silicon Valley, California, and the Asia-Pacific headquarters is located in Shenzhen Shekou Free Trade Zone. At present, the company has large-scale R&D centers and production bases in Shenzhen and Taizhou, Jiangsu.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/03/relia-biological-secures-pre-ipo-equity-financing-raises-hundreds-of-millions-of-yuan/.

Leave a Reply

Please Login to Comment